Ibrance Joins Rival CDK4/6 Inhibitors In English Cancer Drugs Fund
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.